Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 24 Issue 6, June 2006

Phase contrast micrograph of microwells from arrays containing monoclonal antibody-producing hybridomas. The small volumes of the microwells (~1 nL each) in the arrays described by Love et al. ensure that the antibodies produced by single cells are detectable in only 2-4 hours, compared with the 2-7 days required using current approaches, p. 703.

Volume 24 Issue 6

Subscribe

Editorial

Top of page ⤴

News

  • The first ever clinical trial of a therapeutic antibody that binds to natural killer (NK) cell receptors is slated to take place before the year end.

    • Cormac Sheridan
    News

  • Pension managers may be warming up to the idea that much needed high rewards for their funds could come from investing in the high risk private equity biotech sector.

    • John Ransom
    News
Top of page ⤴

News in Brief

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • As equine cloning becomes a commercial reality, what will be the likely impact on the elite world of horse breeding and racing? Stephanie L. Church investigates.

    • Stephanie L. Church
    News Feature
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • Even in sub-Saharan Africa's most progressive nations, agbiotech partnerships are still often poorly oriented to end users, fragmented in scope and of limited impact in achieving the United Nation's Millennium Development Goals.

    • Seife Ayele
    • Joanna Chataway
    • David Wield
    Commentary
Top of page ⤴

Investors Lab

Top of page ⤴

Book Review

Top of page ⤴

Feature

  • Although investors remained cautious of public biotech companies in 2005, acquisitions and research partnerships were on the up.

    • Riku Lähteenmäki
    • Stacy Lawrence
    Feature

  • Compared with the plethora of financial information about the publicly traded elite of the biotech world, little is known about the multitude of private biotech firms. Here, Nature Biotechnology's Editor-at-Large provides an analysis of the financial performance of the privately held biotech sector.

    • John Hodgson
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

  • A method for amplifying DNA from single bacterial cells shows promise for complete genome sequencing.

    • Clyde A Hutchison III
    • J Craig Venter
    News & Views

  • A method for altering the substrate specificity of LuxR proteins may facilitate the engineering of artificial communication systems among cells.

    • Stephen W Michnick
    News & Views

  • Unraveling how a soil-dwelling bacterium kills insects promises to deliver new biopesticides.

    • Richard H ffrench-Constant
    • Nicholas R Waterfield
    News & Views

  • A new approach to reducing the immunological side effects of gene therapy exploits microRNA to knock down transgene expression in immune cells.

    • Waseem Qasim
    • Adrian J Thrasher
    News & Views

  • Spermatogonial stem cells in adult testis may be more versatile than embryonic stem cells.

    • Mito Kanatsu-Shinohara
    • Takashi Shinohara
    News & Views
Top of page ⤴

Analysis

Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Erratum

Top of page ⤴

Corrigendum

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links